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Canada and other countries but less widely adopted in the United States. In this project, we convened an expert panel to create a practical framework for the process of creating, implementing, and maintaining an outpatient AF pathway for emergency physicians to assess and treat AF patients, safely reduce hospitalization rates, ensure appropriate stroke prophylaxis, and effectively transition patients to longitudinal outpatient treatment settings from the ED and/or observation unit. To support local pathway creation, the panel also reached agreement on a protocol development plan, a sample pathway, consensus recommendations for pathway components, sample pathway metrics, and a structured literature review framework using a modified Delphi technique by a technical expert panel of emergency medicine, cardiology, and other stakeholder groups.
A trial fibrillation and flutter (AF) is the most common clinically significant cardiac arrhythmia and most common arrhythmia diagnosed in the emergency department (ED), affecting 1% to 2% of the adult population in the United States.
1,2 AF increases in prevalence with older age, affecting 9% of the population over age 65. 3 As the population ages, the U.S. incidence of AF is expected to more than double from 1.2 million in 2010 to 2.6 million in 2030. 4 Hypertensive heart disease and coronary artery disease are the most common underlying predispositions and frequently seen comorbidities associated with AF. However, AF can also be an uncommon manifestation of acute coronary ischemia without other signs or symptoms. AF is responsible for at least 15% to 20% of all ischemic strokes. 2 Atrial fibrillation is a frequent cause of ED visits and hospitalization. From 2006 to 2011, U.S. ED visits for AF increased by approximately 24% from 133 to 165 visits per 100,000 persons. Hospital admission rates for U.S. ED patients with AF increased from 62.5% to 67% over the same time period. 5 By contrast, in a 2011 study of Canadian patients diagnosed with recent-onset AF, ED admission rates in academic medical centers ranged from 10% to 27%. 6 Threefold higher admission rates in the United States suggest the need to closely examine current approaches in management of AF. 7, 8 The costs for AF care total over $6 billion, about half of which is attributable to inpatient hospitalization. 1, 3, 9, 10 Hospitalization from the ED is a particular focus for cost reductions given studies that show a twofold variation in ED admission rates both within and across facilities. In addition, total hospital admissions across all conditions that originate from the ED account for 8% of national U.S. health care expenditures. 11, 12 Many ED patients are appropriate for safe and effective outpatient management of AF. [13] [14] [15] [16] [17] [18] AF pathways have been tested in mostly academic settings in the United States and Canada and have met primary safety endpoints. These pathways include strategies for early rhythm control, initiation of rate control regimens, and anticoagulation for stroke prophylaxis initiated in the ED. 13, 16, [19] [20] [21] Many of these services can be delivered in the ED or in an observation unit, decreasing the use of inpatient hospital services.
The use of observation status has increased in recent years as payer policies have shifted payments for short-stay inpatient admissions to favor outpatient observation visits. From 2010 to 2014 Medicare observation visits increased 8% per year while inpatient stays decreased by 3% per year. 22 The observation setting-whether in a designated unit or in a medical or ED bed designated as "observation" status-can provide a safe setting for AF patients who are not candidates for cardioversion in the ED, allowing continuation of rate control medications and an opportunity for spontaneous cardioversion or for the patient to receive other additional services beyond the scope of a single ED visit. 23, 24 The additional time afforded by an observation stay (typically up to two midnights) allows for greater assurance that medication changes and new medications are well tolerated and appropriate follow-up has been established. As observation care has proven successful with novel conditions beyond chest pain, such as the evaluation and treatment of carefully selected ED patients with congestive heart failure and transient ischemic attack, it may become an increasingly appealing and appropriate option for ED patients with AF. 25, 26 Despite over a decade of evidence supporting outpatient pathways to prevent avoidable inpatient admissions for patients with AF, barriers to implementation remain in many U.S. hospitals. These barriers arise from a relative discomfort by some emergency physicians to manage AF in the ED and prescribe stroke prophylaxis, as well as the uncertain nature of access to longitudinal care in the United States and the need for close follow-up in this population. In addition, some discomfort may originate from a lack of knowledge, training, and experience with managing AF, as in some hospitals this has traditionally been the domain of inpatient medicine. Tools that directly address these barriers, such as insights into pathway development, sample pathways, and metrics to assess pathway effectiveness and safety, are needed. The goal of this project was to provide multidisciplinary consensus-based guidance for the creation, implementation, and maintenance of an outpatient AF pathway, supported by sample AF resources for use in both academic and community settings. Specifically, these tools are intended to assist local efforts to change practice and include a literature review, consensus recommendations for pathway components, a sample pathway, and sample pathway metrics.
MATERIALS AND METHODS

Study Design and Setting
Using a modified Delphi technique, we convened a panel of content experts to create best practice recommendations for the process of AF pathway development, supported by key AF pathway elements. The Delphi technique is a common framework for bringing groups of experts together via a series of iterative interactions to review key questions and efficiently reach a consensus. 27 We started with a structured literature review to identify evidence-based AF pathway strategies and current best practices, followed by a guideline review to identify current authoritative recommendations.
Literature Review
The panel chair consulted with a medical librarian and performed a structured literature review to create a resource library for panel members. The literature search focused on two main areas in the ED and observation unit settings: the general process of pathway development and specific management of AF in the ED. We used PubMed to search for keyword terms (Data Supplement S1, Tables E1-E4, available as supporting information in the online version of this paper, which is available at http://onlinelibrary.wiley.c om/doi/10.1111/acem.13410/full). In addition, we performed a gray literature search with Google to identify further resources. The panel chair reviewed abstracts and full articles to select those most relevant to the panel's work. This process yielded 137 references related to pathway development and 104 references to AF ED pathways. Panelists were presented a summary of the literature review and online access to PDF copies of all selected papers prior to the first round of voting. Local champions leading AF pathway development efforts also should familiarize themselves with the literature review output via accessing the links in Data Supplement S1 to develop content-specific expertise prior to beginning their own process.
Selection of Participants
Between April and September 2017, we convened a multidisciplinary, geographically diverse expert panel represented by emergency physicians, general cardiologists, electrophysiologists, advanced-practice providers, nurses, hospital administrators, and pharmacists (Table 1) . Panelists possessed a publication history and/or hands-on experience with AF management, anticoagulation initiation, pathway implementation, and transitions of care. They attended an in-person session that featured extensive discussion of key elements in Dallas on June 5, 2017, and submitted electronic comments and votes to preconference and postconference content. To recruit community emergency physician and advanced-practice provider-based panelists, we conducted a call through the American College of Emergency Physicians Observation Medicine Section and Society of Emergency Medicine Physician Assistants, respectively.
Methods for Consensus
The expert panelists were sent publications selected from the literature review and the panel chair drafted preliminary straw man examples of pathway development steps, an AF outpatient pathway, and a list of pathway metrics before calls for review. We used the modified Delphi technique to achieve consensus. This included rounds composed of structured voting, with a slide presentation headed by the chair at the in-person meeting (round two) where information was gathered from the experts, with postmeeting voting and subsequent modification of themes. The expert panel participated in three rounds of modifications with three voting opportunities and a comment period. Items were modified iteratively according to the previous round's discussion and voting. The final panel recommendations represent majority opinions.
RESULTS
The panel first focused on reaching agreement on the process for pathway development and implementation ( Figure 1 ). Areas of discussion surrounded the anticipated duration of each step of the pathway, the step when metrics should be defined and efforts to ensure a collaborative process is followed. The panelists' prior experiences with developing, introducing, and maintaining novel pathways that required interdisciplinary cooperation provided insight into best practices and potential hazards. Themes of inclusiveness of multiple roles and disciplines, clinical and executive champions, adequate resource allocation, and realistic timelines dominated the discussion. The panel then shifted toward creation of a practical ED-based AF pathway example (Figure 2 ), which was intended to serve as a starting point to initiate creation of a local pathway. The panelists agreed that the final version of any institution-specific pathway should be modified from this example to reflect availability of local resources and characteristics of local patient populations to maximize relevance and effectiveness. Examples of resources that would influence elements of the pathway included 1) the ability to perform cardioversion in the ED (i.e., physician and nursing familiarity and comfort with sedation/electrical cardioversion or chemical cardioversion medications), 2) the availability of cardiology consultation in the ED, 3) the availability of an observation unit following an ED visit, 4) availability of expedited outpatient clinic follow-up, 5) emergency physician willingness to initiate oral anticoagulation from the ED, and 6) emergency physician familiarity and willingness to start or transition patients to oral rate control therapy.
The panel agreed on the general strategy of ED cardioversion and discharge home for eligible patients, as seen in the most recent AF pathway examples in the literature. 13, [28] [29] [30] One key area of controversy was the eligibility criteria for ED cardioversion related to anticoagulation status. For example, electrophysiology panelists suggested that initiation of adequate anticoagulation (e.g., a Xa or direct thrombin inhibitor) by the patient within 24 hours of the clear onset of AF would be a scenario wherein ED cardioversion could be acceptable management, even when the patient arrives after 48 hours since the time of onset. A second exception to the 48-hour window for ED cardioversion eligibility would be for patients with evidence of continuous adequate anticoagulation during the preceding 4 weeks, such as warfarin use with therapeutic INR values documented at multiple time points. Another aspect of anticoagulation discussed 
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cardioversion was expected. Ultimately, the panel agreed to recommend anticoagulation but this is an area of ongoing investigation to examine the timing and differences between anticoagulants on important safety outcomes, such as risk for postcardioversion embolic stroke. 31, 32 Several key aspects of the ED and/or observation unit management became focal points for the discussion, and we presented these as consensus statements of the expert panel ( Table 2 ). For example, renal disease is an important consideration because patients with renal failure are likely to be ineligible for medications with an onset of therapeutic effect within the time frame of an ED visit. Another area of panel debate was the choice of electrical versus chemical cardioversion as the initial rhythm control strategy. Furthermore, the choice of chemical cardioversion agent was a topic of contention, as each agent has advantages and disadvantages to consider. For example, the Canadian literature favors intravenous procainamide as both a first-line cardioversion strategy and a medication of choice since it has been widely used for many years with studies reporting a good safety profile and a 60% cardioversion rate, but current U.S.-based specialty society recommendations point toward ibutilide, flecainide, and other agents. 16, [32] [33] [34] [35] The panel compromised by using language that would support a variety of drug choices, providing example guidance only for ibutilide and flecainide in their consensus statements.
Finally, the panel concluded the work by agreeing on a list of suggested metrics for pathway monitoring and quality improvement ( Table 3 ). The purpose of these metrics is to first establish the need for an AF pathway for hospital leadership and clinical staff by illustrating a gap between evidence-based practice and current state. The metrics listed in Table 3 represent those with the highest-level of agreement among the panelists; others with merit were discussed (e.g., cardiology consult rate) but not ultimately included in this list. After pathways go live, metrics such as patient volume trends, adherence to recommended anticoagulation regimens, hospitalization rates, and others track pathway effectiveness internally. We chose a 30-day follow-up window for adverse event tracking since it is a common timeframe in previous AF pathway studies to demonstrate post-ED discharge safety and efficacy. Pathway implementation is also a continuous process, and these metrics serve to highlight areas for future revision and improvement.
DISCUSSION
Atrial fibrillation is a common primary and comorbid disease state encountered in ED patients. Conditionspecific pathways may assist ED physicians by standardizing best practices for patient management and coordinating transitions of care, such as new medication starts and expedited outpatient follow-up. Availability of an ED observation unit expands the population of patients eligible for a pathway by providing an outpatient setting with less time pressure to achieve adequate rate control or spontaneous cardioversion. 23 Several current anticoagulation options aid outpatient medication initiation and follow-up. Creating an effective pathway requires a deliberate approach based on available resources and predetermined metrics focused on patient safety, throughput to help monitor pathway implementation, and ongoing success in managing AF.
Emergency department management of AF appears to vary by country, with providers in the United States historically more likely to prefer the strategy of rate control rather than rhythm control, unlike peers in other western countries such as Canada, Australia, and the United Kingdom. 16, 28, 36 Potential drivers of this practice include prior research suggesting no benefit in outcomes from a preference of rhythm over rate control, the perceived or actual burden on ED resources to perform cardioversion, prior versions of specialty society guidelines, and lack of payer scrutiny of short-stay AF inpatient hospitalizations or readmissions versus other conditions such as chest pain, syncope, and congestive heart failure. 37 More recently, the recognition of patient preference for returning to sinus rhythm has been added to the reasons to advocate for an early cardioversion strategy. [38] [39] [40] [41] Nevertheless, the experience of other countries can provide an example of alternative evidence-based management that results in fewer hospitalizations without evidence of worse outcomes, a result relevant to U.S. EDs faced with heavy burdens of inpatient crowding and ED boarding. 30, 42 As with any clinical pathway, practice adoption may be variable, which is driven by lack of provider awareness and/or training, as well as pathway and guideline deficiencies. An electronic medical record (EMR) may be a useful tool to drive pathway compliance via realtime interaction with the physician to recommend key management interventions. 43 Additionally, tracking performance via these suggested metrics may help • Accompanying diagnosis warranting inpatient care (e.g., acute coronary ischemia, decompensated heart failure, sepsis). † • Renal failure (creatinine clearance < 15 mL/min), if new anticoagulation start anticipated.
• Pregnancy.
• Hemodynamic instability after initial rate control attempt if cardioversion not anticipated (i.e., HR 140-150 beats/min or SBP < 90 mm Hg, ongoing requirement for a drip medication).
• Social barriers to outpatient follow-up (i.e., poor access to follow-up care, anticipated low compliance to patient instructions).
• If observation unit available and anticipated, expected length of stay over institution's maximum (e.g., two midnights).
Rate control
In the ED and observation unit:
• Diltiazem, 0.25 mg/kg IV 91 if SBP > 100 mm Hg followed by 30 mg PO q6h if rate adequately controlled (if rate is not controlled and SBP < 100 mm Hg consider drip [start at 10 mg/hr IV, titrate at 5mg/hr increments to max of 25mg/hr to HR < 100]) or
• Metoprolol, 5-10 mg IV 91 if SBP > 100 mm Hg followed by 25 mg PO q6h if rate adequately controlled (preferred agent for patients already on a beta blocker.
• Adequate rate control for discharge home defined as resting HR < 100 beats/min and ambulatory HR < 110 beats/min with tolerable symptoms after discontinuation of IV therapies.
• Discharge rate control for patients sent home in AF should be lowest dose equivalent of long acting oral medication (i.e., if the patient did well on 30 mg PO diltiazem q6h, discharge patient with 120 mg of long-acting diltiazem once daily, first dose due 6 hours from previous). 32 
Early electrical cardioversion
• Perform synchronized DC electrical cardioversion with procedural sedation (i.e., propofol sedation with preceding analgesia with 200 J with biphasic defibrillator).
• Recommend anterior/posterior pad placement.
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• If performing procedural sedation consult your institution's sedation policy.
Failed early electrical cardioversion
If no evidence of sinus rhythm after initial shock:
• Check pad placement and skin contact.
• If < 200 J used on initial attempt, increase energy to maximum and repeat shock 91.
If transient sinus rhythm after initial shock (early recurrent AF), consider ibutilide.
Chemical cardioversion
Consider for patients who are poor sedation candidates secondary to patient or department resource factors. Options include IV antiarrhythmic Class III (ibutilide), oral antiarrhythmic Class IC (flecainide), among others.
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Ibutilide:
• Pretreat with magnesium 2 g IV 91 over 30 minutes; defibrillator at bedside and pads on patient.
• Ibutilide 1 mg IV over 10 minutes; may repeat same dose 10 minutes after first infusion if still in AF; if still in AF at 30 minutes consider electrical cardioversion.
• Monitor on telemetry 4 hours after cardioversion, watch QTc (risk: Torsades de Pointes).
• Avoid in patients with initial QTc > 450 millisecond. Marked hypokalemia or ejection fraction < 30%.
Flecainide:
• Confirm no significant structural cardiac abnormalities (i.e., TTE within past year or during observation stay showing no wall motion abnormalities/severe valvular disease) or occlusive coronary disease (i.e., low risk or recent normal stress test in observation).
• Achieve adequate rate control prior to cardioversion.
• Flecainide (300 mg PO 91 if ≥70 kg or 200 mg PO 91 if < 70 kg).
• If still in AF after 2 hours, consider electrical cardioversion.
• No need for extended telemetry monitoring.
Cardiology consultation
Consider cardiology consultation in the following situations:
• Failed electrical or chemical cardioversion.
• Anticipated TEE electrical cardioversion.
• Assistance for determining the best plan of care in a medically complex patient ineligible for early cardioversion who is not already followed by a cardiologist.
Anticoagulation in ED/observation:
• Factor Xa or direct thrombin inhibitor otherwise low-molecular-weight heparin or unfractionated heparin per drug administration guideline recommendations if contraindications to Factor Xa or direct thrombin inhibitor present.
49,50
Discharge anticoagulation If patient is discharged in AF:
• Start anticoagulation if CHADS 2 VASc score ≥ 2 and HAS-BLED score < 3. Manage bleeding risk factors if HAS-BLED score ≥ 3; if not modifiable consider delaying anticoagulation start or consultation with anticoagulation expert.
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• Consider starting anticoagulation for patients with a score CHADS 2 VASc score of 0-1 to facilitate outpatient cardioversion.
If patient is discharged in sinus rhythm:
• Use the CHADS 2 VASc score to determine anticoagulation need (0-1 = no anticoagulation; ≥ 2 = Factor Xa or direct thrombin inhibitor; consider either low-molecular-weight heparin with or without warfarin (with bridge) if contraindications to Factor Xa or direct thrombin inhibitors present. 49, 50 • identify such problems and allows leadership to provide feedback. Ideally, such data should be pulled from the EMR without chart review to minimize data collection burden and presented at standing meetings both at the department and at the hospital level. Adding these data to the agenda of an existing quality meeting (e.g., hospital chest pain committee or anticoagulant work group) rather than creating a new meeting is a helpful strategy to maintain visibility and sustain the effort continuously.
Treatment of AF involves multiple disciplines and medical specialties. As a result, an effective pathway requires engagement of relevant local stakeholders both during the pathway development process and after implementation. 13, 29 For example, failure to consider the ED nursing contribution to the pathway will likely lower the likelihood of successful implementation. Some emergency physicians who currently admit patients eligible for the outpatient pathway should be anticipated to express concern over the risks or hassle factor of ED cardioversion and initiation of anticoagulation. Those expected to be most resistant should be engaged individually prior to a group discussion, to allow their concerns to be fully addressed in advance of a larger presentation. Also, lack of support from cardiology or primary care creates barriers to rapid clinic follow up, an essential component of the pathway. Pharmacy and case management support are key resources required to support initiation of anticoagulation and help guide effective drug delivery logistics, historically an area of gap between evidence-based recommendations and actual care in the ED for this population. [44] [45] [46] [47] The process of pathway development should be viewed as a model for multi-stakeholder collaboration. Additionally, pathways must be adapted to reflect the variability across ED resources and patient populations. Sample pathways provide a reference and elements may or may not be relevant in a specific setting; they should be adapted to reflect local resources, address any unique needs of the local patient population, and allow for attending physician judgment.
As hospital crowding and payer policies continue to push emergency physicians to shift eligible patients away from inpatient settings toward outpatient-centric pathways, further study is needed to support these Disposition criteria (hospital admission)
• Deterioration in clinical status, such as worsening or new concerning symptoms (i.e., shortness of breath, chest pain, or inability to tolerate oral medications).
• Failed cardioversion or inadequate rate or symptom control after ED resources have been exhausted.
Disposition criteria (discharge home)
Adequate symptom management and rate control in AF or conversion to sinus rhythm for > 1 hour after discontinuation of all IV medications.
• Evaluation and treatment complete with symptoms resolved or tolerable.
• Follow-up appointment made and communicated to patient; if after hours, appointment requested and confirm next business day.
• Anticoagulation and rate control medication (if needed) plan established.
Outpatient follow-up
Arrange for follow-up clinic visit within 3-to 5-day window (can be cardiology, primary care, or other based on institutional standards; if anticoagulant started, consider anticoagulant clinic for follow-up).
• Ensure that patient's insurance will permit planned clinic follow-up and new medications.
• Perform patient education around AF and new medications.
• Instruct patient around signs and symptoms warranting return to ED. AF = atrial fibrillation/flutter. *Above criteria are modifiable according to individual institutional standards †Examples only, not a comprehensive list practices and identify new opportunities. Key areas of continuing controversy that merit further investigation include how to safely cardiovert patients with delayed or unknown onset of AF in the ED (particularly those recently anticoagulated with a Xa or direct thrombin inhibitor), how a dedicated observation unit can be best used to support the pathway, and the optimal risk/benefit of anticoagulation in this patient population.
LIMITATIONS
Our approach had several limitations. First, a systematic literature review that included level of evidence grading was out of scope for this project; as a result, a structured literature search substituted for a systematic review that met PRISMA standards. 48 Currently available specialty society recommendations include similar content and we did not seek to duplicate it. 32, 49, 50 Second, most of our panelists currently work in an academic setting. Emergency care is predominantly delivered in a community setting; as a result, the panel's example content, such as the consensus pathway, may not directly apply in some common practice settings. However, several panelists have current or former community emergency medicine experience, and their input shaped flexibility in the final recommendations to make them relevant to a wide audience. Third, access to a dedicated observation unit is variable across hospitals, although all hospitals have the capability of designating a patient as observation status. Patients ineligible for cardioversion who also fail rate control efforts in the ED or are still symptomatic may require inpatient care if an ED-based or equivalent alternative observation unit resource is unavailable.
Fourth, the example pathway created by the panel was framed as a pragmatic aid to reflect current specialty society recommendations and typical ED workflows. This specific pathway is a synthesis of prior work and was not specifically studied; thus we do not report outcome data related to the use of the sample pathway. It is intended to be adaptable to local resource availability (i.e., access to cardiology consultation) and will require updating as the evidence evolves. For example, risk scores guiding initiation of anticoagulation to reduce stroke risk (e.g., CHA 2 DS 2-VASc) have been updated several times in recent years and we expect ongoing investigations in these areas. 51 
CONCLUSION
In conclusion, we developed a multistakeholder atrial fibrillation pathway creation and implementation tool with the goal of reducing avoidable hospitalizations and improving adherence to evidence-based anticoagulation regimens to reduce preventable ischemic stroke. Emergency physicians are well suited to lead local efforts to create a pathway, but successful implementation and sustainable effectiveness require support from other stakeholders. New resources such as ED observation units and rapid-onset anticoagulants make larger patient populations eligible for outpatient care plans. Further research is needed to answer key questions that could further enhance the impact of atrial fibrillation pathways.
